Agios Pharmaceuticals Inc (STU:8AP)
€ 45.8 0.8 (1.78%) Market Cap: 2.49 Bil Enterprise Value: 1.59 Bil PE Ratio: 4.05 PB Ratio: 1.61 GF Score: 28/100

Q4 2019 Agios Pharmaceuticals Inc Earnings Call Transcript

Feb 13, 2020 / 01:00PM GMT
Release Date Price: €44.62 (-0.18%)
Operator

Good morning, and welcome to Agios' Fourth Quarter and Full Year 2019 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Holly Manning, Associate Director of Investor Relations.

Holly Manning
Agios Pharmaceuticals, Inc. - Associate Director of IR

Thank you, operator. Good morning, everyone, and welcome to Agios' Fourth Quarter and Full Year 2019 Conference Call. You can access slides for today's call by going to the Investors section of our website, agios.com.

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of U.S. Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot